Aeglea BioTherapeutics Announces Publication of 20 Week Data from Phase 1/2 and Open-Label Extension Studies of Pegzilarginase for the Treatment of Arginase 1 Deficiency in the Journal of Inherited Metabolic Disease

  • George Diaz

Press/Media

Period14 Jul 2021

Media coverage

1

Media coverage

  • TitleAeglea BioTherapeutics Announces Publication of 20 Week Data from Phase 1/2 and Open-Label Extension Studies of Pegzilarginase for the Treatment of Arginase 1 Deficiency in the Journal of Inherited Metabolic Disease
    Media name/outletIndia Pharma News
    Country/TerritoryIndia
    Date14/07/21
    PersonsGeorge Diaz
View all 1
View less

Related content